Sabine Wilhelm Selected Research

7,7'- dimethoxy- (4,4'- bi- 1,3- benzodioxole)- 5,5'- dicarboxylic acid dimethyl ester (BDD)

1/2022	Predictors of pharmacotherapy outcomes for body dysmorphic disorder: a machine learning approach.
1/2022	Early response to cognitive behavioral therapy for body dysmorphic disorder as a predictor of outcomes.
1/2022	An Evaluation of the Body Dysmorphic Disorder Symptom Scale as a Measure of Treatment Response and Remission in Psychotherapy and Medication Trials.
1/2022	Efficacy of App-Based Cognitive Behavioral Therapy for Body Dysmorphic Disorder with Coach Support: Initial Randomized Controlled Clinical Trial.
1/2022	Maladaptive self-focused attention and default mode network connectivity: a transdiagnostic investigation across social anxiety and body dysmorphic disorders.
5/2021	Temporal dynamics of insight in body dysmorphic disorder: An ecological momentary assessment study.
3/2021	Rates of remission, sustained remission, and recurrence in a randomized controlled trial of cognitive behavioral therapy versus supportive psychotherapy for body dysmorphic disorder.
1/2021	Body dysmorphic disorder: a treatment synthesis and consensus on behalf of the International College of Obsessive-Compulsive Spectrum Disorders and the Obsessive Compulsive and Related Disorders Network of the European College of Neuropsychopharmacology.
1/2021	Body dysmorphic disorder and self-esteem: a meta-analysis.
1/2021	Empirically defining treatment response and remission in body dysmorphic disorder.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sabine Wilhelm Research Topics

Disease

67	Body Dysmorphic Disorders (Body Dysmorphic Disorder) 01/2022 - 01/2002
17	Obsessive-Compulsive Disorder (Disorder, Obsessive-Compulsive) 01/2018 - 01/2002
12	Mental Disorders (Mental Disorder) 01/2022 - 01/2002
12	Tics (Tic) 01/2022 - 08/2006
5	Tic Disorders (Tic Disorder) 01/2020 - 05/2010
4	Anorexia Nervosa 02/2015 - 07/2013
3	Major Depressive Disorder (Major Depressive Disorders) 01/2020 - 10/2019
3	Anxiety Disorders (Anxiety Disorder) 12/2019 - 01/2002
3	olfactory reference syndrome 01/2018 - 06/2010
2	Social Phobia 01/2022 - 01/2002
2	Feeding and Eating Disorders (Eating Disorder) 01/2020 - 06/2010
2	Carcinoma (Carcinomatosis) 01/2017 - 09/2004
2	Tourette Syndrome (Tourette's Syndrome) 01/2016 - 11/2013
2	Excoriation Disorder 09/2007 - 01/2002
1	Neurobehavioral Manifestations 01/2022
1	Starvation 01/2021
1	Mood Disorders (Mood Disorder) 01/2019
1	Bipolar Disorder (Manic Depressive Psychosis) 01/2019
1	Disease Susceptibility (Diathesis) 06/2017
1	Inflammation (Inflammations) 01/2017
1	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 01/2017
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2017
1	Infections 01/2016
1	Schizophrenia (Dementia Praecox) 09/2015
1	Overweight 01/2014
1	Thinness 12/2013
1	Body Integrity Identity Disorder 06/2010
1	Hypochondriasis 06/2010
1	Substance-Related Disorders (Drug Abuse) 01/2008
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 06/2007
1	Neoplasms (Cancer) 02/2007
1	Multiple Myeloma 02/2007
1	Sepsis (Septicemia) 01/2007
1	Rheumatoid Arthritis 01/2007
1	Autosomal Dominant Polycystic Kidney (ADPKD) 02/2002
1	Somatoform Disorders (Somatoform Disorder) 01/2002

Drug/Important Bio-Agent (IBA)

66	7,7'- dimethoxy- (4,4'- bi- 1,3- benzodioxole)- 5,5'- dicarboxylic acid dimethyl ester (BDD)IBA 01/2022 - 01/2002
6	Cycloserine (Seromycin)FDA Link 12/2019 - 03/2008
4	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 01/2022 - 08/2012
3	Escitalopram FDA Link 01/2019 - 09/2007
2	Oxytocin (Pitocin)FDA LinkGeneric 01/2020 - 01/2019
2	Biomarkers (Surrogate Marker)IBA 10/2019 - 01/2019
2	ORALIT (ORS)IBA 01/2018 - 01/2016
2	Proteins (Proteins, Gene)FDA Link 02/2007 - 02/2002
1	trans-sodium crocetinate (crocetin)IBA 01/2021
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2021
1	LipidsIBA 01/2021
1	P-2 (P 2)IBA 01/2020
1	Peptides (Polypeptides)IBA 01/2020
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2017
1	LCL161IBA 01/2017
1	Antidepressive Agents (Antidepressants)IBA 01/2017
1	CytokinesIBA 01/2017
1	CaspasesIBA 01/2017
1	Pharmaceutical PreparationsIBA 01/2016
1	dibenzthione (D 47)IBA 01/2014
1	beta-cyclodextrin tetradecasulfate (CTDS)IBA 12/2013
1	Complement System Proteins (Complement)IBA 12/2010
1	Anti-Bacterial Agents (Antibiotics)IBA 07/2010
1	Antipsychotic Agents (Antipsychotics)IBA 05/2010
1	N-Methylaspartate (NMDA)IBA 03/2008
1	DNA (Deoxyribonucleic Acid)IBA 06/2007
1	PicoGreenIBA 06/2007
1	Proteasome InhibitorsIBA 02/2007
1	Immunoglobulins (Immunoglobulin)IBA 02/2007
1	Bortezomib (Velcade)FDA Link 02/2007
1	HMGB1 Protein (HMG1)IBA 01/2007
1	beta CateninIBA 09/2004
1	CationsIBA 02/2002

Therapy/Procedure

15	Therapeutics 01/2022 - 08/2006
3	Drug Therapy (Chemotherapy) 01/2022 - 09/2016
1	Aftercare (After-Treatment) 01/2021
1	Secondary Prevention 09/2016